Sarepta (NASDAQ: SRPT ) is a popular stock in the Fool community, but its inestors have had a tough run lately, watching shares lose half of their value in the past six months. A late-stage trial failure by a competing drug from GlaxoSmithKline and Prosensa potentially squashed Sarepta's chance for an accelerated approval. Or did it?
Sarepta's management recently met with the FDA to discuss the path forward for eteplirsen. Mothers of boys effected by Duchenne muscular dystrophy are filing a petition, but the small size of the phase 2 trial may not be enough to sway the federal regulators.
On this edition of Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass discuss the possible outcomes for Sarepta, what could affect the FDA's decision-making, and how this catalyst could affect the stock.
6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.